Specifically, the ratio of CLU+/αSMA+ CAFs and the ratio of CLU+/HLA-DR+ CAFs was higher in BRCA-mut tumors compared to BRCA-WT tumors (Fig. 1f, g), suggesting that germline mutations in the cancer cells alter tumor CAF compositions. This evidence concerns the gene CLU and cancer.